Research analysts at Barclays assumed coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a research report issued on Monday,Benzinga reports. The firm set an "overweight" rating and a $43.00 price target on the stock. Barclays's target price would indicate a potential upside of 23.71% from the company's previous close.
Separately, Wall Street Zen upgraded Hinge Health to a "hold" rating in a research note on Monday, June 2nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Hinge Health presently has a consensus rating of "Moderate Buy" and an average target price of $46.75.
Get Our Latest Report on HNGE
Hinge Health Trading Down 0.7%
Shares of NYSE HNGE opened at $34.76 on Monday. Hinge Health has a 52-week low of $33.42 and a 52-week high of $43.80.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
